Literature DB >> 27905978

Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I. Final order.

.   

Abstract

The Administrator of the Drug Enforcement Administration is issuing this final order to temporarily schedule the synthetic opioid, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700), and its isomers, esters, ethers, salts and salts of isomers, esters and ethers, into schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act. This action is based on a finding by the Administrator that the placement of U-47700 into schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety. As a result of this order, the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances will be imposed on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle, U-47700.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27905978

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  10 in total

1.  Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace.

Authors:  Michael H Baumann; Susruta Majumdar; Valerie Le Rouzic; Amanda Hunkele; Rajendra Uprety; Xi Ping Huang; Jin Xu; Bryan L Roth; Ying-Xian Pan; Gavril W Pasternak
Journal:  Neuropharmacology       Date:  2017-08-12       Impact factor: 5.250

2.  Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700.

Authors:  Camille Richeval; Jean-Michel Gaulier; Ludovic Romeuf; Delphine Allorge; Yvan Gaillard
Journal:  Int J Legal Med       Date:  2018-11-15       Impact factor: 2.686

3.  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.

Authors:  Michael T Truver; Christina R Smith; Nancy Garibay; Theresa A Kopajtic; Madeleine J Swortwood; Michael H Baumann
Journal:  Neuropharmacology       Date:  2020-06-10       Impact factor: 5.250

4.  U-47700: An Emerging Threat.

Authors:  Saeed K Alzghari; Steven W Fleming; Kerry Anne Rambaran; James E Long; Samantha Burkhart; Jie An; Jakub Furmaga
Journal:  Cureus       Date:  2017-10-22

5.  Updating the list of known opioids through identification and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900).

Authors:  D Fabregat-Safont; X Carbón; M Ventura; I Fornís; E Guillamón; J V Sancho; F Hernández; M Ibáñez
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

6.  Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids.

Authors:  Renata Solimini; Simona Pichini; Roberta Pacifici; Francesco P Busardò; Raffaele Giorgetti
Journal:  Front Pharmacol       Date:  2018-06-20       Impact factor: 5.810

Review 7.  The search for the "next" euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning.

Authors:  Kirti Kumari Sharma; Tim G Hales; Vaidya Jayathirtha Rao; Niamh NicDaeid; Craig McKenzie
Journal:  Forensic Toxicol       Date:  2018-11-28       Impact factor: 4.096

8.  Online surveillance of novel psychoactive substances (NPS): Monitoring Reddit discussions as a predictor of increased NPS-related exposures.

Authors:  Elan Barenholtz; Alex J Krotulski; Paul Morris; Nicole D Fitzgerald; Austin Le; Donna M Papsun; Barry K Logan; William E Hahn; Bruce A Goldberger; Linda B Cottler; Joseph J Palamar
Journal:  Int J Drug Policy       Date:  2021-08-05

9.  On the Horizon: The Synthetic Opioid U-49900.

Authors:  Saeed K Alzghari; Zubair M Amin; Sophie Chau; Steven W Fleming; Kevin Cho; Victor Fung
Journal:  Cureus       Date:  2017-09-12

10.  A Case of Kratom Use: Implications for Managing Addiction and Addressing Comorbidity in Overdose Survivors, and for the Education of Clinicians Who Are Not Addiction Specialists.

Authors:  Joseph H Donroe; David A Fiellin
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.